Artificial Intelligence driven Marketing Communications
Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life” or the “Company”), an adaptive healthcare solutions company, today announced that Dr. Santus Wari has joined the company as Head of National Healthcare for the Republic of Vanuatu.
Dr. Santus Wari is the former Acting Director of the Vanuatu Department of Curative & Hospital Services and former Vanuatu Ministry of Health Director General of Health. He was also the Medical Superintendent for the Vila Central Hospital and Northern Provincial Hospital in Vanuatu at varying times. Dr. Wari served as the Senior Consulting Surgeon for the Ministry of Health during his 25 years as a surgeon and, prior to joining the government of Vanuatu, he gained formal medical training under the supervision of the Australian Medical Support to Vanuatu. He holds Bachelor’s degrees of Medicine and Surgery from The University of the South Pacific and a Post Graduate degree in General Surgery from The Fiji School of Medicine. Serving the medical needs of the Republic of Vanuatu, Dr. Santus Wari retired in 2018.
“Dr. Santus Wari holds a strong reputation in Vanuatu’s medical community, and we’re honored that he has agreed to spearhead operations for the National Network of Community Clinics and Dispensing Pharmacies, to address and provide solutions for the national diabetes epidemic. Further, Dr. Santus Wari joins the research team as a lead investigator for clinical trials for our cannabinoid-based Type 2 diabetes management product, Phoenix Metabolic, adding greater experience in Pacific Island communities,” said Phoenix Life Sciences International CEO Martin Tindall. “As we continue to build out our expert team, I look forward to seeing what our collaborative knowledge, experience, and relationships can bring to our potentially life-changing efforts.”
“Having worked directly with the local hospitals and healthcare clinics in Vanuatu, I have seen first-hand how prominent the country’s diabetes epidemic has become and the need for citizens to have a more accessible, safe and affordable alternative treatment to address the disease,” said Phoenix Life Head of National Healthcare Dr. Santus Wari. “Alongside Phoenix Life, I look forward to not only building out the company’s efforts in Vanuatu, but also helping to change healthcare around the world.”
Phoenix Life, with the assistance of Dr. Wari, plans to continue building out its network of Community Clinics and Dispensing Pharmacies throughout Vanuatu. These clinics will greatly expand the country’s diabetes treatment options by providing preventative blood sugar testing, dispensing pharmacies and other services to promote the health of the local people.
To learn more about Phoenix Life Sciences International, please visit https://phoenixlife.co/ or for the local Vanuatu website to register or for more local information please visit https://phoenixlife.vu.
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available in the U.S.
Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.
Investor Contact: Phone: 1.888.717.5655 or international +1.720.699.7222 E-mail: [email protected] Media Contact: Kathryn Reinhardt CMW Media [email protected] 619-972-3089